Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8%

Disc Medicine, Inc. (NASDAQ:IRON) saw a large increase in short interest in December. As of December 31st, there was short interest totaling 3,790,158 shares, an increase of 53.8% from the December 15th total of 2,464,343 shares. Approximately 10.4% of the company’s stock are sold short. Based on an average daily volume of 785,510 shares, the short-interest ratio is presently 4.8 days. Based on an average daily volume of 785,510 shares, the short-interest ratio is presently 4.8 days. Approximately 10.4% of the company’s stock are sold short.

Disc Medicine Stock Performance

NASDAQ IRON traded down $0.11 on Friday, reaching $70.93. 454,807 shares of the stock were exchanged, compared to its average volume of 643,055. Disc Medicine has a one year low of $30.82 and a one year high of $99.50. The firm has a market capitalization of $2.68 billion, a PE ratio of -13.26 and a beta of 0.87. The company’s 50-day simple moving average is $85.55 and its two-hundred day simple moving average is $72.42. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). Analysts expect that Disc Medicine will post -4.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on IRON shares. UBS Group reissued an “overweight” rating on shares of Disc Medicine in a research report on Thursday. National Bankshares set a $153.00 price objective on shares of Disc Medicine in a research note on Friday, October 17th. Cowen reissued a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a report on Wednesday, October 8th. Finally, Wedbush reiterated an “outperform” rating on shares of Disc Medicine in a research report on Thursday. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Disc Medicine has a consensus rating of “Moderate Buy” and a consensus price target of $119.45.

Insider Activity at Disc Medicine

In other news, insider Rahul Khara sold 6,500 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $78.69, for a total value of $511,485.00. Following the transaction, the insider owned 37,793 shares in the company, valued at approximately $2,973,931.17. This represents a 14.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider William Jacob Savage sold 13,093 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $91.22, for a total value of $1,194,343.46. Following the sale, the insider owned 75,702 shares in the company, valued at approximately $6,905,536.44. This represents a 14.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 274,470 shares of company stock worth $24,896,430 in the last ninety days. 3.64% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Disc Medicine by 3.7% during the third quarter. Vanguard Group Inc. now owns 1,448,059 shares of the company’s stock worth $95,688,000 after acquiring an additional 51,323 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Disc Medicine by 11.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock worth $44,678,000 after acquiring an additional 84,278 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Disc Medicine by 4.7% during the 2nd quarter. Geode Capital Management LLC now owns 598,589 shares of the company’s stock worth $31,705,000 after purchasing an additional 26,605 shares during the period. Vestal Point Capital LP boosted its stake in shares of Disc Medicine by 257.1% during the 3rd quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock worth $33,040,000 after purchasing an additional 360,000 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its holdings in Disc Medicine by 50.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 450,000 shares of the company’s stock valued at $23,832,000 after purchasing an additional 150,000 shares during the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.